ID: ALA1194486

Max Phase: Preclinical

Molecular Formula: C41H45ClN4O2

Molecular Weight: 661.29

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(CCc1ccc2nc(-c3ccccc3)c3c(c2c1)OCCC3)NCCCCCCCNc1c2c(nc3cc(Cl)ccc13)CCCC2

Standard InChI:  InChI=1S/C41H45ClN4O2/c42-30-19-20-32-37(27-30)45-35-16-8-7-14-31(35)40(32)44-24-10-3-1-2-9-23-43-38(47)22-18-28-17-21-36-34(26-28)41-33(15-11-25-48-41)39(46-36)29-12-5-4-6-13-29/h4-6,12-13,17,19-21,26-27H,1-3,7-11,14-16,18,22-25H2,(H,43,47)(H,44,45)

Standard InChI Key:  WZSXQVUTYDCZRO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 661.29

Molecular Weight (Monoisotopic): 660.3231

AlogP: 9.42

#Rotatable Bonds: 13

Polar Surface Area: 76.14

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 8.10

CX LogP: 9.26

CX LogD: 8.52

Aromatic Rings: 5

Heavy Atoms: 48

QED Weighted: 0.12

Np Likeness Score: -0.69

References

1. Ferreira JPS, Albuquerque HMT, Cardoso SM, Silva AMS, Silva VLM..  (2021)  Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).,  221  [PMID:33984802] [10.1016/j.ejmech.2021.113492]

Source

Source(1):

• Scientific Literature